Results 41 to 50 of about 3,074 (210)

Benchmarking Deep Learning Architectures for Predicting Readmission to the ICU and Describing Patients-at-Risk

, 2020
Objective: To compare different deep learning architectures for predicting the risk of readmission within 30 days of discharge from the intensive care unit (ICU).
Barbieri, Sebastiano, Gallagher, Martin, Jorm, Louisa, Kemp, James, Kotwal, Sradha, Perez-Concha, Oscar, Ritchie, Angus   +6 more
core   +1 more source

Clinical and Research Considerations for Patients with Hypertensive Acute Heart Failure [PDF]

, 2016
Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics.
Alan B. Storrow, Daniel J. Lenihan, David J. Lanfear, Douglas B. Sawyer, G. Michael Felker, Gregg C. Fonarow, Gregory J. Fermann, Javed Butler, Jennifer L. Martindale, JoAnn M. Lindenfeld, John R. Teerlink, Judd E. Hollander, Mark E. Dunlap, Michael M. Givertz, Nancy M. Albert, Peter S. Pang, Phillip D. Levy, Sean P. Collins, W. Frank Peacock   +18 more
core   +1 more source

HPLC – Quality by Design Approach for Simultaneous Detection of Torsemide, Spironolactone and Their Degradant Impurities

Pharmaceutical Technology in Hospital Pharmacy, 2018
A simple, highly robust (quality by design (QbD) approach), precise and accurate method using high performance liquid chromatography coupled to mass spectrometry has been established for the simultaneous separation, identification and quantitation of a ...
Bihola Unnati, Prajapati Prajesh, Agrawal Y. K.   +2 more
doaj   +1 more source

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study - A Randomized Clinical Trial [PDF]

, 2016
Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown.
Abbott, J A, Barrett, K A, Bomassi, E, Bonagura, J D, Boswood, A, Church, W M, Deinert, M, Del Palacio, M J F, Estrada, A H, Fox, P R, Fujii, Y, Gordon, S G, Haggstrom, J, Jaudon, J P, Keene, B W, Kresken, J G, Ljungvall, I, Luethy, M W, MacDonald, K A, Menaut, P, Moise, N S, O'Sullivan, M L, Oyama, M A, Patteson, M, Rosenthal, S L, Rush, J, Sanderson, K, Santilli, R A, Saunders, A B, Smith, S, Spier, A, Stepien, R L, Szatmari, V, Tidholm, A, Uechi, M, Watson, P, Wess, G, Woolley, R   +37 more
core   +3 more sources

Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis [PDF]

, 2015
Background: As far as we are aware, no previous systematic review and synthesis of the qualitative/descriptive literature on polypharmacy in anabolic-androgenic steroid(s) (AAS) users has been published. Method: We systematically reviewed and synthesized
AJ Gruber, AJ Gruber, AJ Gruber, AJ McBride, AJ Viera, Astrid Bjørnebekk, B Hegazy, B Larance, C Ahlgrim, C Wilson-Fearon, Cecilie Schou Andreassen, CN Schäfer, CS Cornford, D Hoff, D Moher, D Moher, D Sagoe, D Sagoe, DA Malone Jr, DL Katz, Dominic Sagoe, E Chahla, E Pappa, F Klötz, G Kanayama, G Kanayama, G Kanayama, G McKillop, GS Goldfield, H Angoorani, H Geyer, HB Moss, HB Moss, HG Pope Jr, HG Pope Jr, IBM Corp, J Bilard, JA Smith, JD Wines, Jim McVeigh, JR Hoffman, K Skårberg, K Skårberg, K Skårberg, KA Clauson, L Degenhardt, L Lundholm, LJ Silvester, M Chandler, M Dunn, M Evans-Brown, Marie-Stella Essilfie, MJ Evans-Brown, N Gårevik, P Korkia, P Korkia, P Lenehan, PJ Fudala, PJ Perry, PJ Perry, R Davies, R Peters, R Shaw, RH Strauss, RP Kusserow, RT Dawson, S Darke, SM Filiault, Ståle Pallesen, T Dodge, T Hildebrandt, TA Pagonis, V Tallon, VD Hope, W Rashid   +74 more
core   +2 more sources

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters [PDF]

, 2016
Background Efflux transporters like MDR1 and MRP2 may modulate the pharmacokinetics of about 50 % of all drugs. It is currently unknown how much of the variation in the activities of important drug membrane transporters like MDR1 or MRP2 is determined by
Cordula Sachse-Seeboth, Daniel Sehrt, Jakob B. Hjelmborg, Johannes Matthaei, Jürgen Brockmöller, Matthias Schwab, Mladen V. Tzvetkov, Reinhold Kerb, Ute Hofmann, Valerie Gal   +9 more
core   +4 more sources

Efficacy of torsemide versus furosemide in heart failure: a systematic review and meta-analysis of randomized controlled trials

Archives of Medical Science: Atherosclerotic Diseases
Introduction Loop diuretics are a cornerstone in the symptomatic management of heart failure. There is conflicting evidence regarding potential differences between torsemide and furosemide in their effects on heart failure outcomes.
Mohamed Magdi Eid, Ahmed M Altibi, Mostafa Reda Mostafa, Andrew Takla, Ahmad Salem, Claudine Abdou, Majd Al Deen Alhuarrat, Devesh Rai, Wilbert S. Aronow, Kirolos Barrsoum   +9 more
doaj   +1 more source

Renin-Angiotensin-Aldosterone System Activation and Diuretic Response in Ambulatory Patients With Heart FailurePlain-Language Summary

Kidney Medicine, 2022
Rationale & Objective: Heart failure treatment relies on loop diuretics to induce natriuresis and decongestion, but the therapy is often limited by diuretic resistance.
Jonathan G. Amatruda, Rebecca Scherzer, Veena S. Rao, Juan B. Ivey-Miranda, Michael G. Shlipak, Michelle M. Estrella, Jeffrey M. Testani   +6 more
doaj   +1 more source

Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution Genome evolution and evolutionary systems biology [PDF]

, 2014
© 2014 Janha et al.; licensee BioMed Central Ltd.Background: Cytochrome P450 CYP2C19 metabolizes a wide range of pharmacologically active substances and a relatively small number of naturally occurring environmental toxins.
Janha, RE, Linton, KJ, Shaheen, SO, Sisay-Joof, F, Walton, RT, Worwui, A   +5 more
core   +3 more sources

Pushing Limits: Exploring Torsemide's Potential Through In-Vitro Mucoadhesive Buccal Delivery Characterization [PDF]

, 2023
This study focuses on developing and evaluating mucoadhesive buccal tablets containing Torsemide, utilizing HPMC K-100, Xanthan Gum, and chitosan polymers at varying concentrations.
Ahad, Hindustan Abdul, Dkhar, Becare, Mahalingan, K., Sahani, Pushpa, Syiemlieh, Pynskhemlin   +4 more
core   +2 more sources